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Aims: Data on differences in clinical characteristics and management of COPD in different 
countries and settings are limited. We aimed to characterize the proﬁ  le of patients with COPD 
in a number of countries and their treatment in order to evaluate adherence to recommendations 
of international guidelines.
Method: This was an observational, international, cross-sectional study on patients with 
physician-diagnosed COPD. Demographic and clinical characteristics, risk factors, and treatment 
were collected by their physician via an internet web-based questionnaire developed for the 
study.
Results: A total of 77 investigators from 17 countries provided data on 833 patients. The 
countries with the highest number of patients included were: Argentina (128), Ecuador (134), 
Spain (162), and Hong Kong (153). Overall, 79.3% were men and 81% former smokers, with 
a mean FEV1 = 42.7%, ranging from 34.3% in Hong Kong to 58.8% in Ecuador. Patients 
reported a mean of 1.6 exacerbations the previous year, with this frequency being signiﬁ  cantly 
and negatively correlated with FEV1(%) (r  =  –0.256; p   0.0001). Treatment with short-acting 
bronchodilators and theophyllines was more frequent in Ecuador and Hong Kong compared with 
Spain and Argentina, and in patients belonging to lower socioeconomic levels (p   0.0001 for 
all comparisons). Inadequacy of treatment with inhaled corticosteroids and theophyllines was 
high, with signiﬁ  cant differences among countries.
Conclusions: Differences in the clinical characteristics and management of COPD were 
signiﬁ  cant across countries. Adherence to international guidelines appears to be low. Efforts should 
be made to disseminate and adapt guidelines to the socioeconomic reality of different settings.
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Introduction
Chronic obstructive pulmonary disease (COPD) is an important public healthcare 
problem throughout the world. Despite anti-smoking campaigns, its prevalence and 
mortality rate continue rising every year (Jemal et al 2005). By 2020 it is estimated 
that COPD will be the ﬁ  fth cause of disability and the third cause of death (Pauwels 
et al 2001).
A previous epidemiologic study demonstrated the prevalence of COPD in the 
general Spanish population between 40 and 70 years of age to be of 9.1% (Sobradillo 
et al 2000). However, more importantly, it was observed that 78% of the patients 
identiﬁ  ed with COPD had not been previously diagnosed with the disease, and 60% 
of these patients were not being treated according to the current guidelines (Sobradillo 
et al 2000; Miravitlles et al 2005). Worldwide, the prevalence of COPD in the general 
population is estimated to be 1% across all ages, rising steeply to 8% to 10% or higher 
among those aged 40 years and with nearly 80% of COPD cases remaining undiagnosed 
(Chapman et al 2006; Halbert et al 2006). Most of the information on the characteristics 
of patients with COPD and the patterns of treatment derive from a series of studies International Journal of COPD 2008:3(4) 804
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conducted in North America and Europe (Jackevicius et al 
1997; Miravitlles et al 1999; Roche et al 2001; De Miguel 
et al 2003; Esteban et al 2006). Few studies have provided 
data from countries from other parts of the world, although the 
prevalence of COPD is also high in Latin America (Menezes 
et al 2005), Korea (Kim et al 2005), Taiwan (Wang et al 
2007), China (Zhong et al 2007), and Japan (Fukuchi et al 
2004). Exposure to respiratory risk factors also differ between 
geographic areas (Menezes et al 2005; Zhong et al 2007) and 
these, together with genetic determinants and patterns of 
smoking, may be the reason for the different characteristics 
and severity of COPD across countries (Buist et al 2007).
In recent years, epidemiological studies have demon-
strated a high and increasing burden of COPD worldwide 
(Chapman et al 2006; Halbert et al 2006). Moreover, the 
adherence of treatment to currently accepted guidelines is 
poor in many countries (Miravitlles et al 1999; Roche et al 
2001; Rennard et al 2002; De Miguel et al 2003).
The EPOCA (Enfermedad Pulmonar Obstructiva Crónica 
en Acción) project is an international web-based survey of 
doctors and their COPD patients, aimed at comparing the 
clinical and demographic characteristics, risk factors, and 
treatment of patients with COPD in different areas of the 
world using a common protocol through the internet.
Method
Design
This was a prospective, international, cross-sectional, obser-
vational survey of outpatients diagnosed with COPD. The 
full data collection period included one year, from December 
2005 to December 2006. Data were collected through a web-
enabled database developed in two languages, English and 
Spanish. Physicians interested in COPD were recruited using 
email addresses retrieved from their publications in the ﬁ  eld 
and were invited to participate by email. We aimed to have a 
representation of different geographic areas by contacting lead-
ing investigators who could invite colleagues in their area to 
join the study. Each investigator was provided with a username 
and a password to access an online study questionnaire. They 
were allowed to visualize and modify data of only their own 
patients. None of the investigators received any payment for 
participating in the study. Since the main study objectives were 
descriptive and group comparisons analyses were not planned, 
we did not make a pre-speciﬁ  ed calculation of sample size.
Ethics
The design of the EPOCA website fulﬁ  lled all standards of 
data protection. Since the server was located in Barcelona 
(Spain), the database was declared to the Spanish authorities. 
No data were collected that could help to identify any single 
patient in the database. The study was approved by a central 
ethics committee of the Hospital Clínic of Barcelona, Spain. 
Informed consent forms were available in the website 
for downloading in English and Spanish. Written or oral 
informed consent was obtained for the patients to be included 
in the study, according to local legislation for observational, 
non-interventional studies in each country.
Study population
This was an international, multicenter study in real life 
practice with a large number of investigators in differ-
ent settings; therefore we wanted to minimize the risk 
of misclassiﬁ  cation or misdiagnosis as much as possible 
by not including life-long never smokers. The inclusion 
criteria were: a) aged older than 40 years; b) smokers or 
former smokers of at least 10 pack-years; and c) had forced 
spirometry with a post-bronchodilator FEV1/FVC   70%.
Exclusion criteria were diagnoses of: a) bronchial asthma; 
b) severe bronchiectasis; c) active tuberculosis and any other 
chronic infectious disease.
Study variables
The data collected included age, sex, race, socioeconomic 
and educational level, and risk factors and clinical charac-
teristics of COPD. Socioeconomic level was categorized by 
the investigators into high, intermediate, or low according to 
the gross national income and related to the values for their 
country. Clinical characteristics of COPD included spiromet-
ric results as well as the number of previous exacerbations, 
emergency visits and hospitalizations due to exacerbations in 
the previous 12 months and healthcare utilization. Owing to 
the characteristics of the study, standardization of the spiro-
metric measurements was not possible and each investigator 
was requested to observe American Thoracic Society criteria 
for standardization of spirometric procedures (American 
Thoracic Society 1995). Post-bronchodilator values were 
used for the analysis whenever available.
The treatment patterns identiﬁ  ed included drug treat-
ments, vaccination, rehabilitation, and long-term oxygen 
therapy. Adherence of prescribed treatments to the current 
guidelines was assessed for inhaled corticosteroids (ICS) and 
theophyllines. According to the GOLD guidelines existent 
at the time of data collection (Pauwels et al 2001), ICS were 
indicated in patients with FEV1 less than 50% predicted and 
with one or more exacerbations and/or visits to emergency 
rooms and/or admissions. Theophyllines were indicated International Journal of COPD 2008:3(4) 805
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as a second-line treatment after long-acting beta2-agonists 
(LABAs) and tiotropium in severe patients. To be restrictive 
in the indication for severe patients, we decided to use a cut 
off level of FEV1 less than 30% predicted in patients already 
treated with LABAs and/or tiotropium. For both groups of 
drugs the percentages of not indicated drugs among the 
prescribed and the percentage of not prescribed over the 
indicated was calculated.
Statistical analysis
Main variables are presented as percentages. Countries 
with the largest participation were identiﬁ  ed and clinical 
and treatment characteristics of COPD among the patients 
recruited in these countries were compared. We used a 
parametric test (Student’s t-test) for variables with a normal 
distribution and non-parametric test (Mann-Whitney test) 
for non normally distributed variables. Percentages were 
compared by means of the chi-squared test. A p value less 
than 0.05 was considered signiﬁ  cant.
Factors potentially associated with exacerbations, 
prescription of ICS, combination therapy of LABA + ICS, 
and tiotropium were studied using stepwise logistic 
regression analysis with the statistical package SAS 
version 8.02.
Results
Patient demographic characteristics
A total of 77 investigators from 17 countries included data 
from at least one patient in the database. The total number 
of patients included was 833, representing a mean of 10.8 
patients per investigator. The countries/areas with the highest 
number of recruited patients were: Spain (n = 162), Hong-
Kong (n = 153), Ecuador (n = 134), and Argentina (n = 128); 
these were further analyzed.
Patient demographic characteristics are summarized in 
Table 1. Mean age was 69.5 (SD = 10.2) years, 78.2% of 
participants were men, and only 19.4% were active smokers. 
Mean tobacco consumption for both smokers and ex-smokers 
was 47.7 pack-years (SD = 34 pack-years). Most of the 
patients had attended, either ﬁ  nished (24.5%) or unﬁ  nished 
(29.3%), only primary school, and only 8.3% had a uni-
versity degree. Most individuals were retired (59.4%) and 
only 23.2% were active, either part- or full-time, workers. 
According to the investigator’s perception, 38.2% of patients 
belonged to a lower socioeconomic class, 54.4% to a middle 
class, and 7.2% were ranked as upper class.
There were significant differences in most of the 
demographic characteristics across countries. For instance, 
patients in Hong Kong showed the lowest body mass index 
Table 1 Demographic and socioeconomic characteristics of the study population
Variable Global N = 833 Argentina N = 128 Ecuador N = 134 Spain N = 162 Hong Kong N = 153 p value
Sex, men, % 79.3 71.1 70.9 90.7 90.8  0.0001
Age, years 69.5 (10.2) 66.8 (8.9) 71.7 (12.0) 69.0 (10.2) 74.9 (7.1)  0.0001
BMI, kg/m2 25.0 (5) 25.5 (4.3) 25.6 (5.2) 26.4 (4.8) 21.7 (3.9)  0.0001
Active smokers, % 19 14 18.1 20.1 20 0.53
Pack-years 46.9 (33.1) 58.1 (31.1) 33.4 (31.7) 46.9 (29.9) 45.2 (33.8)  0.0001
Biomass exposure, % 22.9 15.7 32.3 8.1 43  0.0001
Comorbidity, % 42.5 38.1 41.4 63.4 42.1  0.0001
Socioeconomic, %
  High 7.2 7.9 12.5 6.3 1.3  0.0001
  Intermediate 53.2 62.2 50.8 67.1 21.0
  Low 39.6 29.9 36.7 26.6 77.7
Residence, %
  Rural 11.5 7.1 12.7 18.1 6.0  0.0001
  Intermediate 6.9 1.6 11.2 16.9 0
  Urban 81.6 91.3 76.1 65.0 94.0
Education, %
  Up to primary 53.5 39.1 46.3 65.0 86.7  0.0001
  Up to secondary 27.7 45.3 32.8 26.1 10.6
  Up to postgraduate 18.7 15.6 20.9 8.9 2.6
Abbreviations: BMI, body mass index.International Journal of COPD 2008:3(4) 806
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(21.7), the oldest mean age (74.9 years), and the highest 
proportion of males (90.8%). Mean tobacco consumption was 
highest in Argentina (58.1 pack-years) and highest exposure 
to biomass smoke was in Hong Kong and Ecuador (43% 
and 32.3%, respectively) (p   0.0001 for all comparisons) 
(Table 1).
Characteristics of COPD
Dyspnea on exertion was the most frequent symptom 
(97.8%), with 54.8% of patients presenting dyspnea 
MRC degree III or IV. Mean FEV1% predicted was 
42.7% (SD = 17.8%). The patients presented a mean 
of 1.6 (SD = 2) exacerbations, 1.5 (SD = 2.5) visits to the 
general practitioner and 2.4 (SD = 2.6) visits to the chest 
specialist in the previous 12 months (Table 2). The frequency 
of exacerbations was signiﬁ  cantly, albeit weakly, correlated 
with COPD severity, as measured by FEV1(%), giving a 
correlation factor (r) of −0.256 (p   0.0001) (Figure 1).
Analysis of differences among countries showed several 
highly signiﬁ  cant items. Chronic respiratory symptoms, 
cough and sputum, were most frequent in Ecuador (87.4% 
and 92.1%, respectively). Mean FEV1 ranged from 34.3% in 
Hong Kong to 58.8% in Ecuador. Use of healthcare resources 
also differed by country. The mean number of admissions 
ranged from 1 per patient per year in Hong Kong to 0.4 in 
Ecuador and the mean number of visits to a chest specialist 
from 1.8 in Spain and Hong Kong to 4.6 in Argentina 
(p   0.0001 for all comparisons) (Table 2).
Treatment of COPD
The most frequently prescribed treatment for COPD was 
short-acting beta-agonists (SABA) (74.8%) followed by 
ipratropium (48.3%), with large differences between coun-
tries. SABAs were prescribed in a range from 90.1% in Hong 
Kong to 21.1% in Spain. Tiotropium was used by 73.9% of 
patients in Spain and only 1.9% in Hong Kong. Combined 
treatment of LABA and ICS was used by 45.9% of patients, 
ranging from 12.5% in Hong Kong to 72.8% in Argentina 
(all differences were statistically signiﬁ  cant, Table 3). Oral 
treatment was prescribed less frequently; theophyllines were 
used by 25.3% of the sample, with maximum frequency in 
Hong Kong (46.6%). Only 15.6% of patients were follow-
ing a rehabilitation program, mostly in Argentina (30.5%). 
Interestingly, 58.6% had received the anti-inﬂ  uenza vaccine 
the previous year, with the lowest percentage in Ecuador 
(22.6%). Antipneumococcal vaccine was administered to 
32.5%, with almost no use in Hong Kong (0.7%) and a 
maximum in Argentina (64.4%).
When compared with recommendations based on inter-
national guidelines (Pauwels et al 2001), we observed non-
compliance with these recommendations in a signiﬁ  cant 
number of patients. Speciﬁ  cally, 306 patients fulﬁ  lled indica-
tions for chronic treatment with ICS and 527 were regularly 
treated with ICS. Up to 27.8% of those with an indication 
for ICS treatment were not receiving them, and, according 
to the guidelines, 41.9% of patients treated with ICS did not 
fulﬁ  l the indications for treatment. This inadequacy varied 
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Figure 1 Correlation between lung function (FEV1(%)) and the frequency of exacerbations the previous year (r = −0.256; p   0.0001).International Journal of COPD 2008:3(4) 807
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signiﬁ  cantly among countries (Table 4). Theophyllines were 
administered to 222 patients while 123 had indications for 
treatment with this drug. However, up to 79.6% of the patients 
with indication for theophyllines were not receiving them, 
and, according to the guidelines, 26.6% of patients treated 
with theophyllines had no indication. Differences were, 
again, large and signiﬁ  cant among countries (Table 4).
Differences according to estimated 
social class
Patients of a lower socioeconomic class were older and had a 
more severe impairment of FEV1(%) than patients belonging to 
an upper class. They were also more exposed to biomass smoke 
(36.1% vs 13.5% and 18.6% for low, middle, and high class, 
respectively, p   0.0001). Lower class patients tended to require 
more visits to emergency rooms and admissions for exacerba-
tions (p = 0.058 and p = 0.083, respectively) (Table 5).
Treatments differed according to the class; SABAs, 
LABAs, ipratropium, and theophyllines were more 
frequently prescribed to lower class patients and tiotropium 
and combination therapy LABA + ICS were less frequently 
used by lower class patients (all comparisons p   0.0001). 
Rehabilitation was more frequent in upper class patients 
(31.5% compared with 15.7% and 13.4% in middle and lower 
classes, respectively; p = 0.0036) (Table 5).
Analysis of factors associated 
with exacerbations and prescribed drugs
Stepwise regression analysis identiﬁ  ed the variables signiﬁ  cantly 
associated with the frequency of exacerbations categorized as 
0–1 versus more than 1. Older age, increasing baseline dyspnea, 
and use of ICS were associated with an increased frequency of 
exacerbations in the model (Table 6a).
In terms of pharmacologic treatment, use of ICS was 
signiﬁ  cantly associated with more impaired lung function 
and the presence of expectoration. Patients belonging to the 
upper class, active smokers, and Spanish were less likely to 
use ICS alone compared with lower classes, former smokers, 
and patients from Argentina, Ecuador, and Hong Kong 
(Table 6b). In contrast, Spanish patients were more likely 
to use combination therapy with LABA + ICS than patients 
from Ecuador or Hong Kong, and patients with secondary 
schooling, former smokers, or with chronic cough were more 
likely to be prescribed the combination of LABA + ICS 
Table 2 Characteristics of COPD
Variable Global N = 833 Argentina N = 128 Ecuador N = 134 Spain N = 162 Hong Kong N = 153 p value
Years of evolution 10.1 11.1 8.1 14.3 8.8 <0.0001
Symptoms, %
  Dyspnea Degree 0 2.2 0 5.9 1.5 0 <0.0001
 Degree  1 11.5 2.6 16.8 10.3 3.7
 Degree  2 31.4 36.2 32.8 30.1 28.3
 Degree  3 34.3 36.2 26.9 32.3 47.8
 Degree  4 20.5 25.0 17.6 25.0 20.1
  Chronic cough, % 69.6 71.2 87.4 76.6 52.3 <0.0001
 Sputum,  % 70.5 75.4 92.1 59.4 63.8 <0.0001
Lung function
  FVC, ml 2312.2 (920.5) 2472.5 (804.9) 2295.1 (750.2) 2709.9 (1016.9) 1448.9 (602.5) <0.0001
  FVC,% predicted 59.7 (19.4) 62.2 (16.0) 65.4 (17.7) 66.8 (19.5) 40.3 (14.8) <0.0001
 FEV1, mL 1143.8 (518.7) 1147.2 (465.4) 1406.0 (627.1) 1279.5 (547.0) 841,6 (391.4) <0.0001
 FEV1, % predicted 42.7 (17.8) 41.1 (15.4) 58.8 (23.5) 44.3 (17.3) 34.3 (13.9) <0.0001
 FEV1/FVC 50.6 (14.5) 47.0 (13.7) 60.9 (15.9) 48.0 (13.1) 59.0 (14.2) <0.0001
During the last year
  Number of exacerbations 1.6 (2.0) 2.0 (1.9) 0.9 (1.4) 1.8 (1.9) 1.9 (3.0) <0.0001
  Emergency visits 0.9 (1.5) 1.3 (1.8) 0.3 (0.7) 0.9 (1.5) 1.3 (2.1) <0.0001
  Admissions 0.6 (1.0) 0.5 (1.1) 0.4 (0.8) 0.6 (1.0) 1.0 (1.3) <0.0001
  IC admissions 0.1 (0.3) 0.2 (0.5) 0.0 (0.3) 0.1 (0.4) 0.0 (0.3) <0.0001
  Visits to GP 1.5 (2.5) 2.6 (3.7) 1.6 (3.2) 2.0 (3.2) 1.2 (2.5) <0.0001
  Visits to chest specialist 2.4 (2.6) 4.6 (3.8) 2.8 (2.7) 1.8 (1.8) 1.8 (2.0) <0.0001
Abbreviations: FVC, forced vital capacity; FEV1, forced expiratory volume in the ﬁ  rst second; IC, intensive care; GP, general practitioner.International Journal of COPD 2008:3(4) 808
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(Table 6c). Finally, use of tiotropium was associated only 
with geographic variables, with patients from Argentina, 
Ecuador, or Hong Kong being less likely to be treated with 
this drug than patients from Spain (Table 6).
Discussion
This study shows that there are signiﬁ  cant and relevant 
differences in the clinical characteristics, exposure to risk 
factors, and patterns of management of patients with COPD 
in different areas of the world. Differences in genetic back-
ground may account for part of the variations shown by the 
results. However, different toxic exposures, differences in 
socioeconomic and living conditions, and differences in 
education levels also exist and may be responsible, at least 
in part, for the variations observed in the manifestations of 
COPD. Epidemiological studies have demonstrated impor-
tant variations in the prevalence of smoking in young adults 
across countries and, as a consequence, a large variation in 
the prevalence of chronic bronchitis (Cerveri et al 2001) and 
COPD (De Marco et al 2004). However, the same authors 
indicated that only 30% of the geographical variability in 
prevalence could be explained by differences in smoking 
habits, suggesting other factors such as environmental expo-
sure or genetic background as contributors to this variability 
(Cerveri et al 2001).
The clinical characteristics of patients with COPD 
have been carefully studied in clinical trials (Calverley 
et al 2007). However, due to the restrictive inclusion and 
Table 3 Treatment administered for stable COPD
Variable Global N = 833 Argentina N = 128 Ecuador N = 134 Spain N = 162 Hong Kong N = 153 p value
Inhaled treatment, %
  SABA 74.8 85.6 69.5 75.3 97.4  0.0001
 Ipratropium 48.3 52.5 30.4 21.1 90.1  0.0001
 Tiotropium 35.5 33.9 40.6 73.9 1.9  0.0001
 LABA 9 2.5 13.3 9.1 2.6 0.0007
 ICS 21.8 12.7 31.2 5.6 44.7  0.0001
 LABA/ICS 45.9 72.8 35.9 68.3 12.5  0.0001
Oral treatment, %
 Teophyllines 25.3 18.6 26.6 7.1 46.6  0.0001
 Mucolytics 10.1 5.9 13.2 20.4 1.3  0.0001
  Oral corticosteroids 4.4 3.4 11.7 3.5 0  0.0001
Other, %
 LTOT 21.1 14.4 17.9 24.6 17.7 0.18
 Rehabilitation 15.6 30.5 3.1 4.9 7.9  0.0001
 Antiinﬂ  uenza vaccine 58.6 72.0 22.6 80.3 48.7  0.0001
 Antipneumococcal vaccine 32.5 64.4 18.7 43.6 0.7  0.0001
Abbreviations: SABA, short-acting beta2 agonist; LABA, long-acting beta2-agonist; ICS, inhaled corticosteroid; LTOT, long-term oxygen therapy.
Table 4 Inadequate treatment for stable COPD
Variable Global N = 833 Argentina N = 128 Ecuador N = 134 Spain N = 162 Hong Kong N = 153 P value
Inhaled corticosteroids
Indicated (n = 306)
Prescribed (n = 527)
  Indicated, not prescribed 27.8 11.3 18.7 17.4 49  0.0001
  Prescribed, not indicated 41.9 38.6 65.1 33.3 33.3  0.0001
Theophyllines
Indicated (n = 123)
Prescribed (n = 222)
  Indicated, not prescribed 79.6 85 72.2 92.9 0 0.008
  Prescribed, not indicated 26.6 4.5 26.4 0 33.8 0.0016International Journal of COPD 2008:3(4) 809
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Table 5 Demographic and clinical characteristics of patients according to estimated social class
Variables Low N = 324 Intermediate N = 436 High N = 59 p value
Sex, men 76.5 81.9 72.8 0.091
Age, years 71.3 (9.6) 68.8 (10.2) 63.4 (10.5)  0.0001
Active smoker 16.9 20.2 24.1 0.34
Pack-years 45.6 (33.2) 46.7 (31.6) 53.3 (39.6) 0.49
Biomass exposure 36.1 13.5 18.6  0.0001
Years of evolution 9.3 (8.5) 10.7 (10.3) 10 (9.1) 0.34
Comorbidity 40.2 44.8 37 0.32
Baseline dyspnea 0.007
 Degree  0 2.4 2 2
 Degree  1 6.3 13.7 26
 Degree  2 30.5 32.1 26
 Degree  3 37.5 32.6 30
 Degree  4 23.1 19.4 16
Lung function
  FVC, mL 2012.5 (829.2) 2442.4 (885.3) 3033.5 (1116.5)  0.0001
  FVC, % 55.5 (19.5) 61.5 (18.4) 69.2 (19.9)  0.0001
 FEV1, mL 1053.2 (485.8) 1164.4 (515.5) 1487.8 (587.1)  0.0001
 FEV1, % 42.1 (18.4) 42.1 (17.0) 47.4 (18.1) 0.1311*
 FEV1/FVC, % 53.8 (15.2) 48.2 (13.7) 50.5 (13.3) 0.0002
Previous 12 months
  Medical visits GP 1.5 (2.4) 1.6 (2.8) 1.1 (1.5) 0.47
  Medical visits specialist 2.4 (2.2) 2.5 (2.9) 2.2 (2.6) 0.43
  Exacerbations 1.7 (2.4) 1.5 (1.7) 1.4 (1.5) 0.74
  Emergency visits 1.1 (1.8) 0.8 (1.3) 0.6 (1.3) 0.058
  Admissions 0.7 (1.2) 0.5 (0.8) 0.5 (0.8) 0.083
Treatment
 SABA 83.6 71.1 53.7  0.0001
 Ipratropium 64 39.4 24.1  0.0001
 Tiotropium 22.5 42.4 57.4  0.0001
 LABA 7.5 7.6 29.6  0.0001
 ICS 34.3 13.7 9.2  0.0001
 LABA/ICS 34.3 54.6 44.4  0.0001
 Theophyllines 35.6 23.7 22.2 0.0014
 Mucolytics 6.5 14.4 9.2 0.0033
 Rehabilitation 13.4 15.7 31.5 0.0036
 LTOT 21.9 20.6 22.2 0.8988
 Antiinﬂ  uenza vaccination 56.2 62.2 48.1 0.067
 Antipneumococcal  vaccination 23.8 38.9 35.1  0.0001
*p = 0.0447 between high and low social class.
Abbreviations: FVC, forced vital capacity; FEV1, forced espiratory volume in the ﬁ  rst second; GP, general practitioner; SABA, short-acting beta2-agonist; LABA, long-acting 
beta2-agonist; ICS, inhaled corticosteroid; LTOT, long-term oxygen therapy. 
exclusion criteria, these characteristics differ significantly 
from those of COPD patients in general practice. In fact, 
a Swedish study demonstrated that less than 20% of 
patients with COPD attended by general practitioners 
share characteristics with patients included in clinical 
trials (Herland et al 2005). Therefore, surveys conducted 
in real clinical practice in different areas of the world 
with broad inclusion criteria are required to identify the 
characteristics, risk factors, and patterns of management 
of COPD in real life.International Journal of COPD 2008:3(4) 810
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Table 6 Multivariate stepwise regression models of dependent variables signiﬁ  cantly and independently associated with the following 
independent variables: frequency of exacerbations (0–1 versus  1), treatment with ICS, combination therapy LABA + ICS and tiotropium 
(all presented as yes versus no)
a) Frequency of exacerbations
Variable Point estimate 95% conﬁ  dence limits p value
Age  75 vs 65–75 yrs 0.948 0.596–1.508 0.8223
Age  75 vs  65 yrs 2.088 1.280–3.406 0.0032
Dyspnea II vs 0–I 4.399 1.618–11.962 0.0037
Dyspnea III vs 0–I 6.223 2.308–16.782 0.0003
Dyspnea IV vs 0–I 14.249 5.110–39.735  0.0001
Inhaled corticosteroids 2.535 1.611–3.991  0.0001
b) Treatment with inhaled corticosteroids
Variable Point estimate 95% conﬁ  dence limits p value
FEV1  50% vs  50% 1.994 1.059–3.754 0.0326
Expectoration 2.595 1.457–4.619 0.0012
Low class vs high class 5.875 1.907–18.098 0.0020
Middle class vs high 
class
4.667 1.620–13.448 0.0043
Former vs active 
smoker
4.663 2.386–9.113  0.0001
Argentina vs Spain 1.599 0.762–3.358 0.2148
Ecuador vs Spain 1.484 0.447–4.923 0.5193
Hong Kong vs Spain 0.185 0.088–0.388  0.0001
c) Treatment with combination LABA + ICSs
Variable Point estimate 95% conﬁ  dence limits P value
Education secondary vs primary 1.689 1.031–2.766 0.0373
Education postgraduate vs primary 0.925 0.482–1.778 0.8160
Cough 1.756 1.073–2.875 0.0252
Former vs active smoker 3.139 1.754–5.617 0.0001
Argentina vs Spain 1.110 0.628–1.962 0.7203
Ecuador vs Spain 0.181 0.101–0.326  0.0001
Hong Kong vs Spain 0.073 0.039–0.137  0.0001
d) Treatment with tiotropium
Variable Point estimate 95% conﬁ  dence limits P value
Former vs active smoker 1.442 0.803–2.590 0.2198
Argentina vs Spain 0.166 0.096–0.286  0.0001
Ecuador vs Spain 0.234 0.135–0.403  0.0001
Hong Kong vs Spain 0.007 0.002–0.22  0.0001
Data from international surveys of patients with COPD 
in real life are scarce. Two previous surveys identiﬁ  ed 
patients through random telephone calls (Rennard et al 2002; 
Miravitlles et al 2007). The Confronting Survey performed 
in 6 European countries, the US, and Canada demonstrated 
the signiﬁ  cant impact of COPD on daily life activities and 
how patients underestimate disease severity. Furthermore, 
only 45% of patients had undergone spirometry for diagnosis 
(Rennard et al 2002). Similarly, in a large survey conducted 
in Spain in 6,758 adults, the prevalence of chronic respiratory International Journal of COPD 2008:3(4) 811
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symptoms was 36%, but only 56% of the individuals with 
symptoms consulted a physician and of these, only 42% 
underwent spirometry (Miravitlles et al 2006). The Perceive 
Study, conducted in 5 European countries and the US demon-
strated the burden associated with the exacerbations of COPD 
and the impact of the exacerbations on daily life activities 
(Miravitlles et al 2007a). In contrast with the current study, 
no conﬁ  rmation of the diagnosis or severity of COPD was 
possible because of the lack of spirometry in the aforemen-
tioned surveys. Moreover, they collected information only on 
patients from Europe and North America and no data from 
Asia-Paciﬁ  c or Latin America were available. In our study 
only patients with conﬁ  rmed COPD by spirometry were 
included and most of the patients had post-bronchodilator 
values. However, a few patients had only one value registered 
for spirometry. Most were severe patients who needed to take 
their bronchodilators to relieve their severe dyspnea before 
attending the clinics and perform spirometry; therefore, their 
values can be considered post-bronchodilator values. Addi-
tionally, although we recognize the importance of COPD in 
never smokers, we recruited only patients who were either 
smokers or ex-smokers to avoid misclassiﬁ  cation of patients 
with other respiratory diseases such as asthma.
Recent well-conducted epidemiological studies have 
provided information on the burden of the disease in those 
areas. The PLATINO project observed a prevalence of COPD 
(GOLD II to IV) in Latin America ranging from 2.9% in 
Mexico City to 7.1% in Montevideo, again highlighting the 
importance of geographical variation (Menezes et al 2005). 
Using the same protocol, the BOLD initiative, performed in 
12 sites around the world, demonstrated a signiﬁ  cant varia-
tion in the prevalence of COPD (GOLD II to IV), ranging 
from 8.5% in males in Reykjavik to 22.2% in Cape Town and 
from 3.7% in women in Hanover to 16.7% in Cape Town. 
Interestingly, signiﬁ  cant heterogeneity was observed between 
sites, especially in women (Buist et al 2007). These differ-
ences can be observed among different areas of the same 
country, as was demonstrated in a Spanish study in 7 dif-
ferent cities, in which the prevalence of COPD ranged from 
4.9% to 18% (Sobradillo et al 2000). Not only prevalence 
but also severity of impairment in functional status and 
perceived health may vary in different racial groups within 
the same country, as demonstrated in different population 
groups in the US (Adams et al 2006). At least part of these 
differences can be caused by exposure to other risk factors, 
such as biomass smoke exposure (Ramirez-Venegas et al 
2006) or environmental exposure (Montnémery et al 2001). 
A signiﬁ  cant exposure to biomass fuel was declared by 42% 
of the COPD patients in Hong Kong and in 32% in Ecuador, 
compared with only 8% in Spain or 15% in Argentina. Other 
possibilities are the different perception of symptoms, which 
have demonstrated to be related to cultural factors in some 
racial groups (Han et al 2005).
We observed signiﬁ  cant differences in the characteristics 
and management of the disease according to the socioeconomic 
status of the patients. It is important to point out the exist-
ing limitations for adequate classiﬁ  cation of socioeconomic 
status among different countries. However, the results 
obtained are consistent with other published national 
series (Montnémery et al 2001; Ellison-Loschmann et al 
2007; Hegwald and Crapo et al 2007). The current results 
demonstrate a higher exposure to biomass fuel in patients 
with lower socioeconomic status and better lung function 
in upper classes. Treatment also showed some differences, 
with a higher use of old, cheaper, SABAs and theophyllines 
and a lower use of tiotropium and combination therapy 
with LABA + ICS in patients of lower class and education. 
This variation in the use of drugs may largely be due to the 
economic level of the patients since national health coverage 
was poor in the countries showing the highest differences. 
These results concur with other epidemiological surveys 
which demonstrated a significant negative correlation 
between lung function and socioeconomic status (Hegewald 
and Crapo 2007). However, there is a lack of evidence of the 
long-term impact of inadequate or insufﬁ  cient treatment of 
COPD in patients of lower socioeconomic status, as observed 
in our study.
Exacerbations are a frequent event in the natural history 
of COPD. Our patient population had had a mean of 1.6 
episodes the previous year and the frequency of exacerbations 
was signiﬁ  cantly associated with an older age and a more 
severe baseline dyspnea. There was a weak but signiﬁ  cant 
correlation between a more impaired FEV1(%) and more 
frequent exacerbations (r = −0.256; p   0.0001). The rela-
tionship between impaired lung function and more frequent 
exacerbations has been observed in clinical trials (Burge 
and Wedzicha 2003) and observational studies (Miravitlles 
et al 1999), but it has also been demonstrated in this study in 
heterogeneous populations from different countries, which 
together reinforces the relationship between the natural 
history of the disease and the frequency of exacerbations.
Most patients received treatment for COPD and this 
treatment differed widely among countries, suggesting that 
implementation of international guidelines is not uniform 
around the world. SABAs are widely used, but more new 
and expensive drugs such as tiotropium and combination International Journal of COPD 2008:3(4) 812
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therapy with LABA + ICS are more frequently prescribed 
in countries with a higher economic level and in patients of 
higher socioeconomic classes. In fact, country was the only 
variable signiﬁ  cantly associated with prescription of the three 
drugs analyzed in multivariate models. The lack of adher-
ence to treatment guidelines for COPD has been extensively 
demonstrated in previous studies (Jackevicius et al 1997; 
Miravitlles et al 1999; Roche et al 2001; Rennard et al 2002; 
De Miguel et al 2003; Esteban et al 2006; Miravitlles et al 
2007b). Our results highlight this problem and identify some 
of the aspects related to the prescription of different drugs. 
Another interesting observation is the analysis of prescription 
of theophyllines and ICS. Evolutionary studies have dem-
onstrated that theophyllines have been replaced by the use 
of ICS in patients with COPD over time (Van Andel et al 
1999). However, the use of theophyllines is still very frequent 
in countries such as Hong Kong and Ecuador, probably for 
economic reasons. According to the guidelines at the time of 
data collection, there was a lack of adjustment in the use of 
these two drugs. According to the guidelines, 41.9% of the 
prescriptions of ICS were not prescribed correctly and, con-
versely, in 27.8% of the cases in which they were indicated, 
the ICS were not prescribed. Similarly, a large survey on 
11,973 patients with COPD in Spain showed that 69% of 
patients with mild COPD were receiving ICS regularly 
(Viejo-Bañuelos et al 2006). A recent study has shown that 
some patients with COPD receiving ICS had clinical char-
acteristics similar to asthma (Miravitlles et al 2007b) which 
could justify its use even if FEV1 is above 50% predicted (Siva 
et al 2007). Most patients with an indication of theophyllines 
were not receiving them, perhaps because of the risk of side 
effects, whereas 26.6% of patients treated with theophyllines 
should have received other more appropriate drugs.
The EPOCA study was an attempt to characterize COPD 
patients and patterns of management in different countries 
by using the same protocol and with a simple and fast data 
collection through a web-enabled database on the internet. 
This is one of the few observational studies performed in 
COPD patients using this new technology (Miravitlles et al 
2002). Despite its relatively small sample size, it has allowed 
the identiﬁ  cation of signiﬁ  cant differences in the clinical char-
acteristics and management of COPD across countries. The 
results do not aim to be fully representative of the populations 
of COPD patients in each of the countries participating. 
The selection of investigators was not random or weighted 
according to the population of the countries. To perform such 
a full-scale representative survey would be a tremendous 
task, clearly beyond the scope and the possibilities of our 
study. However, keeping this limitation in mind, our results 
demonstrate, at an international level, the large variability 
of characteristics of COPD patients and their management. 
The results obtained have shown that the characteristics of 
patients with COPD vary in different countries and patterns 
of management differ according to socioeconomic factors. 
A signiﬁ  cant number of patients were not receiving treatment 
according to guidelines, which may result in suboptimal 
effects of therapy. More efforts are required to disseminate 
and implement international guidelines and attempt to adapt 
these guidelines to the socioeconomic reality of each setting. 
The national scientiﬁ  c societies may play an important role 
in disseminating the guidelines through national key opinion 
leaders, local publications translated into their own languages 
and local scientiﬁ  c meetings.
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